Press Releases

19.11.2018 | Nanion Technologies is pleased to welcome Dr. Ronald Knox to the team

LIVINGSTON, N.Y. USA, 19. November 2018: Nanion is pleased to announce the recent hire of Dr. Ronald Knox as Account Executive, who brings 18+ years of experience in drug discovery, target validation and translational research in neuroscience, cardiovascular and immunotherapies.

Within his new role, he will help drive business development and support for the CardioExcyte 96 and Syncropatch 384/768PE systems. Dr. Knox will leverage his Biopharma and academic networks to better understand the evolving landscape of CV ion channel safety pharmacology to help strengthen Nanion’s strategic support and commitment to the implementation of technology platforms that are comprehensively aligned with the global “Comprehensive In Vitro Proarrhythmia Assay” (CiPA) initiative.

Read the full press release here.

Back to Overview


New Genedata Screener®APC Functionality and Integration with Nanion SyncroPatch 384PE at SLAS2017
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.